Research Square
October 11, 2026
Kanokwan Wongkhueng, Kedsaraporn Kenbubpha, Palida Phalasak et al.
preprint
Abstract Objectives Mindfulness-based cognitive therapy (MBCT) has rarely been tested in non-Western inpatient services or delivered by nurses. This trial evaluated a culturally adapted, nurse-led group MBCT programme for Thai inpatients. Method Ninety-four inpatients with moderate to severe ICD-10 depressive disorder at a Thai psychiatric hospital were randomised 1:1 to MBCT plus routine...
Journal of Affective Disorders Reports
October 11, 2026
Elizabeth K. Stierman, Sarah Clifford, Briana E. Kramer et al.
Objective This umbrella review synthesizes evidence about the effectiveness of mindfulness interventions to improve mental health during pregnancy and postpartum. Methods We searched MEDLINE/PubMed, Scopus, Embase.com, PsycInfo, CINAHL, and the Cochrane Database of Systematic Reviews for systematic reviews published between January 1, 2015 and June 26, 2026. We included reviews of randomized...
British Journal of Clinical Psychology
October 9, 2026
Russunan Jantarapakdee, Ratchaneekorn Upasen, Penpaktr Uthis et al.
Abstract Objectives This study evaluated the effectiveness of an integrated, application‐supported mindfulness‐based cognitive therapy (MBCT) programme in reducing depressive symptoms among adolescents with non‐suicidal self‐injury (NSSI). Methods An open‐label, two‐arm randomized controlled trial was conducted in two public secondary schools in Thailand. The schools were randomly allocated to...
Translational Psychiatry
October 8, 2026
Friederike Holze, Kristian Larsen, Brice Ozenne et al.
Abstract Classic psychedelics, including lysergic acid diethylamide (LSD), are currently under investigation for the treatment of major depressive disorder (MDD). Cognitive dysfunction is common in MDD, but effects of psychedelic treatment on cognitive brain function, measured by magnetic resonance imaging, are sparsely reported. The present study investigated effects of LSD treatment on...
Translational Psychiatry
October 6, 2026
Nadia S. Hejazi, Mina Kheirkhah, Robin Chholak et al.
Insomnia and anxiety frequently co-occur with treatment-resistant depression (TRD). This study examined short-term changes in depression, anxiety, and insomnia symptoms post-ketamine in TRD and their inter-relationships. Seventy-one patients with TRD were assessed at baseline and 24 h after intravenous ketamine (0.5 mg/kg). Depression, anxiety, and insomnia were measured using the...
Brain Research Bulletin
October 6, 2026
Ziyi Hua, Yongqiang Shu, Li Li et al.
INTRODUCTION: This study investigated changes in multiband amplitude of low-frequency fluctuations in patients with major depressive disorder following a 2-week combination treatment regimen of esketamine and sertraline, and examined the associations between ALFF changes and clinical symptom improvement. METHODS: Forty patients with major depressive disorder (MDD) received esketamine (0.25...
Psychological Medicine
October 6, 2026
Avery Chan Eun, Kevin H. Yang, Joseph J Palamar
Psilocybin use has increased in the US alongside promising therapeutic potential for depression, raising concerns that individuals may forgo conventional mental health treatment for unsupervised psilocybin use. However, no nationally representative studies have examined whether psilocybin use is associated with differential treatment utilization or perceived unmet need for mental health care...
Cogent Arts and Humanities
October 5, 2026
Khaled Al-Kassimi, Layal Hmaidi
Mainstream secular psychology is grounded in an epistemological framework that privileges reason while largely excluding revelation, thereby limiting its capacity to engage the spiritual dimensions of contemporary mental health and socio-political crises. Yet recent decades have witnessed growing scholarly and clinical interest in non-secular epistemologies that affirm the spiritual essence of...
Research Square
October 5, 2026
Anette Kjellgren, Johan Lundberg, Hampus Yngwe et al.
preprint
Abstract Psilocybin treatment has emerged as a promising intervention for Major Depressive Disorder (MDD). However, the contribution of psychotherapeutic support to treatment outcomes remains unclear. This study explored therapists' descriptions of their work during a randomized, double-blind, placebo-controlled psilocybin treatment phase II trial for MDD. Nine therapists participated in...
Pharmacopsychiatry
October 2, 2026
Masami Murao, Daiki Setoyama, Yasuyuki Matsumoto et al.
Abstract This study investigated the antisuicidal effects of repeated intravenous ketamine in patients with treatment-resistant depression and explored associations between suicidal ideation and temporal changes in selected plasma biomarkers to identify potential biomarkers. This secondary analysis of an open-label trial included outpatients with treatment-resistant depression who received four...